| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
248,779 |
232,637 |
$9.56M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
119,846 |
119,208 |
$7.05M |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
44,249 |
40,841 |
$2.85M |
| S9083 |
Global fee urgent care centers |
12,877 |
11,771 |
$225K |
| 0001A |
|
3,942 |
3,858 |
$143K |
| 0002A |
|
3,630 |
3,591 |
$139K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,502 |
5,274 |
$92K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
3,653 |
3,406 |
$48K |
| 0004A |
|
915 |
912 |
$36K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
19,812 |
18,164 |
$30K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
15,747 |
14,174 |
$20K |
| 0071A |
|
461 |
461 |
$18K |
| 0072A |
|
433 |
433 |
$17K |
| 81002 |
|
35,032 |
34,208 |
$7K |
| 87800 |
|
5,113 |
5,047 |
$7K |
| 0012A |
|
162 |
157 |
$5K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,283 |
4,110 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
4,543 |
4,446 |
$5K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
4,894 |
4,722 |
$4K |
| 87428 |
|
1,607 |
1,575 |
$4K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
5,549 |
5,283 |
$3K |
| 0011A |
|
193 |
187 |
$3K |
| 0003A |
|
87 |
87 |
$3K |
| 93000 |
|
1,317 |
1,313 |
$3K |
| 69210 |
|
2,157 |
2,127 |
$3K |
| 81025 |
|
4,265 |
4,211 |
$3K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,424 |
2,367 |
$1K |
| 82962 |
|
2,683 |
2,663 |
$1K |
| 85018 |
|
1,470 |
1,460 |
$689.83 |
| 99070 |
|
1,124 |
1,102 |
$540.82 |
| 99000 |
|
487 |
486 |
$352.97 |
| 90714 |
|
86 |
86 |
$251.04 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
538 |
537 |
$166.96 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
400 |
396 |
$117.15 |
| 99205 |
Prolong outpt/office vis |
210 |
210 |
$81.87 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
29 |
28 |
$68.73 |
| 92081 |
|
49 |
49 |
$60.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
88 |
88 |
$51.06 |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
1,355 |
1,348 |
$43.85 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
647 |
638 |
$24.47 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
263 |
260 |
$0.00 |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
327 |
323 |
$0.00 |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
840 |
833 |
$0.00 |
| 99382 |
|
53 |
53 |
$0.00 |
| 10060 |
|
12 |
12 |
$0.00 |
| 99383 |
|
317 |
316 |
$0.00 |
| 99384 |
|
328 |
326 |
$0.00 |
| 99385 |
|
136 |
136 |
$0.00 |
| 88141 |
|
111 |
111 |
$0.00 |
| 65205 |
|
12 |
12 |
$0.00 |